A*STAR to receive $107.48M up front & success-based development & commercialization milestones. Boehringer Ingelheim will be responsible for the research, preclinical, clinical development & commercialization of targeted cancer therapies using Abs from A*STAR
Boehringer to get exclusive rights globally to research, develop & commercialize products based on a tumor-specific Abs from A*STAR. EDDC showed the ability of the Abs to target cancer cells with different therapy approaches
The collaboration allows Boehringer to strengthen its tumor cell-directed ADC & immune cell-targeted (T-cell engager) portfolio for highly targeted cancer treatments. A*STAR’s GIS & IBB generated Abs that target Ags found in gastric cancer cells
Ref: Businesswire | Image: Boehringer Ingelheim
